David Steffin
@davidsteffin.bsky.social
Cell therapy trials for solid tumors, pediatric bone marrow transplant
Very promising news and an honor to be a part of this report! @bcmhouston.bsky.social @texaschildrens.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma - Nature Medicine
In an extended follow-up of a phase 1 trial evaluating a first-generation GD2-directed CAR-T cell therapy in patients with neuroblastoma, one patient has had a sustained clinical response for over 18 ...
www.nature.com
February 19, 2025 at 5:00 PM
Very promising news and an honor to be a part of this report! @bcmhouston.bsky.social @texaschildrens.bsky.social
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by David Steffin
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
rdcu.be/d2faz
rdcu.be/d2faz
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
Nature - We evaluate the effects in humans of interleukin-15 co-expression on glypican-3 (GPC3) chimeric antigen receptor (CAR) T cells and demonstrate that IL-15 increases the expansion,...
rdcu.be
December 3, 2024 at 3:46 AM
IL15 increases the expansion of CAR T cells and induces antitumor responses in patients with GPC3+ solid tumors (i.e. liver cancer).
rdcu.be/d2faz
rdcu.be/d2faz
Promising results from our phase 1 trials using GPC3-CAR T cells co-expressing IL-15 in relapsed/refractory solid tumors. @natureportfolio.bsky.social @bcmhouston.bsky.social
@andrasheczey.bsky.social
@andrasheczey.bsky.social
https://www.nature.com/articles/s41586-024-08261-8
t.co
December 3, 2024 at 9:13 PM
Promising results from our phase 1 trials using GPC3-CAR T cells co-expressing IL-15 in relapsed/refractory solid tumors. @natureportfolio.bsky.social @bcmhouston.bsky.social
@andrasheczey.bsky.social
@andrasheczey.bsky.social